Antibody-targeted chemotherapy for the treatment of relapsed acute myeloid leukemia

American Journal of Managed Care

Volumn 6, Issue 18 SUPPL., 2000, Pages

  Williams, J P ^a   Handler, H L ^a  

^a Towers Perrin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; CD33 ANTIGEN; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; HEMOPOIETIC GROWTH FACTOR; IDARUBICIN; MONOCLONAL ANTIBODY; MYLOTARG; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; ANTIBODY TARGETED CHEMOTHERAPY; BLEEDING; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CARDIOTOXICITY; DOSE RESPONSE; DRUG TARGETING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; LEUKEMIA REMISSION; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; RELAPSE; REVIEW; THROMBOCYTOPENIA; UNITED STATES; VOMITING;

ACUTE DISEASE; ADULT; ANTIBIOTICS, AMINOGLYCOSIDE; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG THERAPY; HUMAN; LEUKEMIA, MYELOID; RECURRENCE; SURVIVAL RATE; UNITED STATES;

EID: 0033788449     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Acute myeloid leukemia
2. Leukemia - Adult acute: What is it?
3. Survival with acute myeloid leukemia
4. Clinical studies of new 'biologic' approaches to therapy of acute myeloid leukemia with monoclonal antibodies and immunoconjugates
5. FDA Approves chemotherapy agent mylotarg for leukemia
6. Chronic myeloid leukemia: Biology and therapy
7. Cellular characteristics of acute leukemia cells simultaneously expressing CD13/CD33, CD7 and CD19
8. Acute leukemias
9. Acute and chronic myeloid leukemia
10. Congenital abnormalities in children with acute leukemia: A report from the Children's Cancer Group
11. Fanconi anemia and leukemia: Tracking the genes
12. Atomic bomb and acute leukemia
13. Cigarette smoking and leukemia
14. The process of leukemogenesis
15. Distinct cytogenetic and clinicopathologic features in acute myeloid leukemia after occupational exposure to pesticides and organic solvents
16. The incidence of secondary leukemias
17. The molecular pathogenesis of treatment-induced (secondary) leukemias: Foundations for treatment and prevention
18. Myelodysplasia
19. The biology of chronic myeloid leukemia
20. Adult acute leukemia
21. Treatment of resistant disease
22. Treatment of advanced acute leukemia with allogeneic bone marrow transplantation from unrelated donors
23. Disappointments in treating acute leukemia in the elderly
24. AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: Results from the MRC's 9th AML trial
25. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival
26. Prevalence and mortality rate of congestive heart failure in the United States
27. The toxicity of cytarabine
28. Prognostic significance of chromosomal abnormalities in acute nonlymphocytic leukemia: A study of 343 patients
29. Prognostic value of immunophenotyping in acute myeloid leukemia: Australian Leukaemia Study Group
30. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
31. Treatment of the elderly patient with acute leukaemia
32. Prognostic factors in adult AML
33. Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy: A Southwest Oncology Group study
34. Acute myeloid leukemia in patients more than 50 years of age: Special considerations in diagnosis, treatment and prognosis
35. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: A randomized phase III study of the European organization for research and treatment of cancer leukemia group
36. Management of acute myeloid leukemia in elderly patients
37. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation
38. Treatment of relapsed acute myeloid leukemia with idarubicin and intermediate-dose cytarabine
39. Combination of mitoxantrone and etoposide in refractory acute myelogenous leukemia - An active and well-tolerated regimen
40. Combination of rubidazone and cytosine arabinoside in the treatment of first relapse in acute myelocytic leukemia
41. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: A multicenter randomized placebo-controlled trial (EMA91 Trial)
42. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial
43. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor in the treatment of acute myeloid leukemia and acute lymphoblastic leukemia
44. Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen
45. The sialoadhesins - A family of sialic-acid dependent cellular recognition molecules within the immunoglobulin superfamily
46. Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms
47. Surface marker abnormalities in myelodysplastic syndromes
48. The immunophenotype of blast transformation of chronic myeloid leukemia: A high frequency of mixed lineage phenotype in 'lymphoid' blasts and a comparison of morphologic, immunophenotypic, and molecular findings
49. Cell surface markers in multiple myeloma
50. Calicheamicin gamma 1l: An antitumor antibiotic that cleaves double-stranded DNA site specifically
51. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia
52. Re-induction of complete remissions in adults with acute non-lymphocytic leukemia
53. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031)
54. A randomized, double-blind placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia